A top federal appeals court threw out its IRS regulation that implements key Obamacare health insurance subsidies.» Read More
The number of nonpaying Obamacare enrollees is going to be huge, says Jake Novak.
Some states whose governors were hostile toward Obamacare exceeded enrollment projections, while some big boosters fell short.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
HHS Secretary Kathleen Sebelius says the enrollment tally exceeded expectations, and "demonstrated brisk demand for quality, affordable coverage."
The WHO’s recent warning about germs resistant to antibiotics has raised questions about what pharma companies are doing to fight this.
A report released Wednesday said one-third of people who signed up for health insurance through new federal exchanges hadn't paid their first month's premium.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Danish insulin manufacturer has posted 15 percent growth in first-quarter operating profit but cut its sales outlook for 2014.
Four companies that charged New Yorkers as much as 55 percent interest for medical loans will pay 317 borrowers about $230,000 to settle usury claims.
Two proposals in Congress are taking aim at deadly superbugs. But it's not exactly clear to some experts just what the right medicine should be.
A majority of the nation's states either declined or failed to improve in nearly two dozen health indicators from 2007 to 2012, a new report said.
Ian Read, CEO of Pfizer, flew into London for a round of meetings with politicians and investors ahead of an expected fresh bid for AstraZeneca.
WellPoint reported profit that beat analysts' expectations and said individual exchanges were operating at a profit.
GlaxoSmithKline's sales fell 10%, highlighting the pressures behind last week's decision to trade more than $20 billion of assets with Novartis.
A new NBC News/Wall Street Journal poll shows that 44 percent of Americans now approve of Obama's job performance as Obamacare enrollment grows.
At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.
Merck reported better-than-expected quarterly earnings, helped by cost cuts and asset sales, but revenue came in slightly below expectations.
Today, wearable devices can monitor our health, track our diets -- and potentially save our lives. How?
Would you mind paying a fee at restaurants, supermarkets, and gas stations to help merchants offer health insurance to employees? One survey says yes.
Women who get chemotherapy for breast cancer may end up unemployed for a very long time, researchers reported on Monday.
Get the best of CNBC in your inbox
Crumbs' failure should not surprise anyone. Many chains have risen and fallen with flash-in-pan fads.
From girls who play with food, to video gamers and toy collectors, you'd never guess who's getting rich on YouTube
If you call one of these 10 states home, your home has plenty of room for improvement.